Anti-CD47 Monoclonal Antibody–Drug Conjugate: A Targeted Therapy to Treat Triple-Negative Breast Cancers

Triple-negative breast cancers (TNBCs) are frequently recurrent due to the development of drug resistance post chemotherapy. Both the existing literature and our study found that surface receptor CD47 (cluster of differentiation 47) was upregulated in chemotherapy-treated TNBC cells. The goal of thi...

Descripción completa

Detalles Bibliográficos
Autores principales: Si, Yingnan, Zhang, Ya, Guan, Jia-Shiung, Ngo, Hanh Giai, Totoro, Angela, Singh, Ajeet Pal, Chen, Kai, Xu, Yuanxin, Yang, Eddy S., Zhou, Lufang, Liu, Runhua, Liu, Xiaoguang (Margaret)
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402537/
https://www.ncbi.nlm.nih.gov/pubmed/34452008
http://dx.doi.org/10.3390/vaccines9080882

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402537/
https://www.ncbi.nlm.nih.gov/pubmed/34452008
http://dx.doi.org/10.3390/vaccines9080882

Ejemplares similares